Recombinant Human Claudin-18.2 (CLDN18.2)-VLPs (Active)

This recombinant human claudin-18.2 (CLDN 18.2) is prepared in mammalian cells. Its target gene encodes the full human claudin-18.2 (CLDN 18.2), containing a 10xHis-tag at the C-terminus. The CLDN 18.2 protein has been validated to be active through a functional ELISA. Immobilized human CLDN 18.2 protein can bind to the recombinant anti-CLDN 18.2 monoclonal antibody. And the EC₅₀ is 5.225-9.256 ng/ml. In the WB assay, this CLDN 18.2 protein was detected by the mouse anti-6xHis monoclonal antibody. Three bands appeared on the gel electrophoresis, respectively corresponding to monomer, homodimer, homotrimer of the CLDN 18.2.

CLDN 18.2, the isoform of CLDN 18, is a tight junction protein exclusively expressed in differentiated epithelial cells of gastric mucosa under normal physiological conditions. Studies have demonstrated that CLDN 18.2 was highly expressed in primary gastric malignancies and post-metastatic types of cancer, including carcinomas of the pancreas, esophagus, ovaries, and lungs. Therefore, CLDN 18.2 has become an ideal target for researchers to develop immunotherapies for solid tumors such as gastric cancer and pancreatic cancer.